Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 16 to 21 of 21 results for upadacitinib

  1. Ruxolitinib cream for treating moderate atopic dermatitis after topical corticosteroids and calcineurin inhibitors ID6602

    In development Reference number: GID-TA11809 Expected publication date:  03 June 2027

    Technology appraisal guidance
    In development

  2. Upadacitinib for treating moderately to severely active systemic lupus erythematosus [TSID12366]

    Awaiting development Reference number: GID-TA12021 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Upadacitinib for treating moderate to severe hidradenitis suppurativa in people 12 years and over [ID6666]

    Awaiting development Reference number: GID-TA11825 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]

    Discontinued Reference number: GID-TA10597

    Technology appraisal guidance
    Discontinued

  5. Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (TA715)

    Evidence-based recommendations on adalimumab, etanercept, infliximab and abatacept for adults with moderate rheumatoid arthritis who have tried conventional DMARDs but they have not worked.

    Technology appraisal guidance
    Published
    14 July 2021
    View recommendations

    Sections for TA715

  6. Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)

    Evidence-based recommendations on filgotinib (Jyseleca) for moderate to severe rheumatoid arthritis in adults.

    Technology appraisal guidance
    Published
    24 February 2021
    View recommendations

    Sections for TA676